[
  {
    "ts": null,
    "headline": "Corporate giants retreat from board diversity mandates, Bloomberg reports",
    "summary": "Investing.com -- The corporate landscape continues to shift as major American firms move to dismantle formal diversity requirements for their governing boards. According to a Bloomberg report, American Express Company (NYSE:AXP), Deere & Company (NYSE:DE), and Johnson & Johnson (NYSE:JNJ) have officially abandoned specific diversity criteria previously used to select new directors. This pivot follows intensifying pressure from conservative shareholder activists who argue that such mandates prior",
    "url": "https://finnhub.io/api/news?id=a83f527c1b52bb0eba2fe7b3bbef2e8291b0d3910cebc09e0847f075f6f252b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771543833,
      "headline": "Corporate giants retreat from board diversity mandates, Bloomberg reports",
      "id": 139152753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- The corporate landscape continues to shift as major American firms move to dismantle formal diversity requirements for their governing boards. According to a Bloomberg report, American Express Company (NYSE:AXP), Deere & Company (NYSE:DE), and Johnson & Johnson (NYSE:JNJ) have officially abandoned specific diversity criteria previously used to select new directors. This pivot follows intensifying pressure from conservative shareholder activists who argue that such mandates prior",
      "url": "https://finnhub.io/api/news?id=a83f527c1b52bb0eba2fe7b3bbef2e8291b0d3910cebc09e0847f075f6f252b2"
    }
  },
  {
    "ts": null,
    "headline": "RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) that is recurrent or metastatic, PD-L1-positive, and human papillomavirus (HPV)-unrelated. Data were presented during a plenary session at th",
    "url": "https://finnhub.io/api/news?id=d70cb5874f399e86d667b3f73cdd35921d0a311fb0706e821f43e4af0b9bcbbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771538400,
      "headline": "RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer",
      "id": 139152754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) that is recurrent or metastatic, PD-L1-positive, and human papillomavirus (HPV)-unrelated. Data were presented during a plenary session at th",
      "url": "https://finnhub.io/api/news?id=d70cb5874f399e86d667b3f73cdd35921d0a311fb0706e821f43e4af0b9bcbbf"
    }
  },
  {
    "ts": null,
    "headline": "Compass Diversified Subsidiary The Honey Pot Co. Announces Appointment of Janis Smith-Gomez as Chair of the Board",
    "summary": "WESTPORT, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Honey Pot Company, LLC (“The Honey Pot Co.” or “the Company”), a leading “better-for-you” feminine care brand and subsidiary of Compass Diversified (NYSE: CODI) (“CODI”), announces the appointment of Janis Smith-Gomez as Chair of its Board of Directors, effective January 1, 2026. Ms. Smith-Gomez joined the Company’s Board in April 2024 and has brought commercial and marketing expertise developed through leadership roles across consumer goods",
    "url": "https://finnhub.io/api/news?id=e5a931edfac3db7b4f2e57525b13ac7d1eac52f322ee98a805fefaf4efabf98e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771535400,
      "headline": "Compass Diversified Subsidiary The Honey Pot Co. Announces Appointment of Janis Smith-Gomez as Chair of the Board",
      "id": 139152095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "WESTPORT, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Honey Pot Company, LLC (“The Honey Pot Co.” or “the Company”), a leading “better-for-you” feminine care brand and subsidiary of Compass Diversified (NYSE: CODI) (“CODI”), announces the appointment of Janis Smith-Gomez as Chair of its Board of Directors, effective January 1, 2026. Ms. Smith-Gomez joined the Company’s Board in April 2024 and has brought commercial and marketing expertise developed through leadership roles across consumer goods",
      "url": "https://finnhub.io/api/news?id=e5a931edfac3db7b4f2e57525b13ac7d1eac52f322ee98a805fefaf4efabf98e"
    }
  },
  {
    "ts": null,
    "headline": "PRESS: J&J explores USD20 billion sale of orthopedics unit - Bloomberg",
    "summary": "PRESS: J&J explores USD20 billion sale of orthopedics unit - Bloomberg",
    "url": "https://finnhub.io/api/news?id=d8e2dc15595209f8d5ef8361d80183bc72c6870bb5d859b197f9f9c14a8d904e",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771531186,
      "headline": "PRESS: J&J explores USD20 billion sale of orthopedics unit - Bloomberg",
      "id": 139151771,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d8e2dc15595209f8d5ef8361d80183bc72c6870bb5d859b197f9f9c14a8d904e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson explores $20 billion sale of orthopedics unit, Bloomberg News reports",
    "summary": "Feb 19 () - Johnson & Johnson is preparing a potential sale of the orthopedics unit that it has ‌been planning to separate, with big buyout firms already ‌circling, Bloomberg News reported on Thursday, citing people familiar with the matter. The ​business, known as DePuy Synthes, could be valued at more than $20 billion in a sale, according to Bloomberg.",
    "url": "https://finnhub.io/api/news?id=7641fed0e325042be5b2abea958c7e4a035933058edd6229cfc19f2f1425052e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771530583,
      "headline": "Johnson & Johnson explores $20 billion sale of orthopedics unit, Bloomberg News reports",
      "id": 139151400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Feb 19 () - Johnson & Johnson is preparing a potential sale of the orthopedics unit that it has ‌been planning to separate, with big buyout firms already ‌circling, Bloomberg News reported on Thursday, citing people familiar with the matter. The ​business, known as DePuy Synthes, could be valued at more than $20 billion in a sale, according to Bloomberg.",
      "url": "https://finnhub.io/api/news?id=7641fed0e325042be5b2abea958c7e4a035933058edd6229cfc19f2f1425052e"
    }
  },
  {
    "ts": null,
    "headline": "J&J Explores $20 Billion-Plus Sale of Orthopedics Unit",
    "summary": "The business, known as DePuy Synthes, could be valued at more than $20 billion in a sale, the people said, asking not to be identified discussing confidential information.  J&J is assembling documents and financials for DePuy Synthes before it meets with possible buyers in the coming weeks, the people said.  Several large private equity firms are considering teaming up to potentially buy out the unit, they said.",
    "url": "https://finnhub.io/api/news?id=00d4e2a124229d36e6810833d72d347ff2b109f92c3ab48631a03be5cbc2e2b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771528587,
      "headline": "J&J Explores $20 Billion-Plus Sale of Orthopedics Unit",
      "id": 139152096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The business, known as DePuy Synthes, could be valued at more than $20 billion in a sale, the people said, asking not to be identified discussing confidential information.  J&J is assembling documents and financials for DePuy Synthes before it meets with possible buyers in the coming weeks, the people said.  Several large private equity firms are considering teaming up to potentially buy out the unit, they said.",
      "url": "https://finnhub.io/api/news?id=00d4e2a124229d36e6810833d72d347ff2b109f92c3ab48631a03be5cbc2e2b5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility",
    "summary": "Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.",
    "url": "https://finnhub.io/api/news?id=5dfe22ed0ccc9c36439f4e39cdd59aa9a6a8a74a2f4e7bc1875c3ce2a008c364",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771526057,
      "headline": "Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility",
      "id": 139152097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.",
      "url": "https://finnhub.io/api/news?id=5dfe22ed0ccc9c36439f4e39cdd59aa9a6a8a74a2f4e7bc1875c3ce2a008c364"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces Data From Phase 1b/2 OrigAMI-4 Trial Of Investigational Subcutaneous Amivantamab, Hyaluronidase-lpuj In Combination With PD-1 Inhibitor Shows 56% Overall Response Rate; Consistent Safety Profile",
    "summary": "Johnson &amp; Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with",
    "url": "https://finnhub.io/api/news?id=b9584f71209be457619e92aaacb32f5743cfd4cba422b4913780e0eb3147966e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771524179,
      "headline": "Johnson & Johnson Announces Data From Phase 1b/2 OrigAMI-4 Trial Of Investigational Subcutaneous Amivantamab, Hyaluronidase-lpuj In Combination With PD-1 Inhibitor Shows 56% Overall Response Rate; Consistent Safety Profile",
      "id": 139160459,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with",
      "url": "https://finnhub.io/api/news?id=b9584f71209be457619e92aaacb32f5743cfd4cba422b4913780e0eb3147966e"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)",
    "summary": "Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)",
    "url": "https://finnhub.io/api/news?id=3d412d999b3ead5a46259c91bc2deb00915875556729d48e83daea77550fc3d9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771522226,
      "headline": "Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)",
      "id": 139152426,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3d412d999b3ead5a46259c91bc2deb00915875556729d48e83daea77550fc3d9"
    }
  },
  {
    "ts": null,
    "headline": "What a Supreme Court tariff ruling may mean for your money",
    "summary": "The Supreme Court is poised to rule on a broad swath of President Donald Trump's tariff agenda. The decision carries big implications for household finances.",
    "url": "https://finnhub.io/api/news?id=005644ac949b3957c9f47e2b01de5645ffcf6a74ea03def1e623e37df71324ce",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771518504,
      "headline": "What a Supreme Court tariff ruling may mean for your money",
      "id": 139161945,
      "image": "https://image.cnbcfm.com/api/v1/image/108257956-1769555459222-gettyimages-2257975411-US_GOV_FUNDING.jpeg?v=1771542064&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "The Supreme Court is poised to rule on a broad swath of President Donald Trump's tariff agenda. The decision carries big implications for household finances.",
      "url": "https://finnhub.io/api/news?id=005644ac949b3957c9f47e2b01de5645ffcf6a74ea03def1e623e37df71324ce"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: I'm Buying Post Earnings",
    "summary": "Bristol-Myers: I'm Buying Post Earnings",
    "url": "https://finnhub.io/api/news?id=cdb38d6e053024dce2899de1c2886c57b17b603f9010e585e65eda1ea4d54fd1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771517342,
      "headline": "Bristol-Myers: I'm Buying Post Earnings",
      "id": 139151899,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=cdb38d6e053024dce2899de1c2886c57b17b603f9010e585e65eda1ea4d54fd1"
    }
  },
  {
    "ts": null,
    "headline": "'J&J Explores $20 Billion-Plus Sale of Orthopedics Unit' - Bloomberg",
    "summary": "https://www.bloomberg.com/news/articles/2026-02-19/j-j-explores-20-billion-plus-sale-of-orthopedics-unit",
    "url": "https://finnhub.io/api/news?id=1dbf1a3bbdb692d22ad2b27b6e15bd3c9239cb0d38be41fd579801a0daa767ab",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771514595,
      "headline": "'J&J Explores $20 Billion-Plus Sale of Orthopedics Unit' - Bloomberg",
      "id": 139160460,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "https://www.bloomberg.com/news/articles/2026-02-19/j-j-explores-20-billion-plus-sale-of-orthopedics-unit",
      "url": "https://finnhub.io/api/news?id=1dbf1a3bbdb692d22ad2b27b6e15bd3c9239cb0d38be41fd579801a0daa767ab"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure",
    "summary": "PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.",
    "url": "https://finnhub.io/api/news?id=9653a7ee14db41a617001a00b9963f36ca8eb7ff89e98130873c68d34698864f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771514100,
      "headline": "Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure",
      "id": 139150406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.",
      "url": "https://finnhub.io/api/news?id=9653a7ee14db41a617001a00b9963f36ca8eb7ff89e98130873c68d34698864f"
    }
  },
  {
    "ts": null,
    "headline": "J&J to build $1bn US CGT manufacturing site in Pennsylvania",
    "summary": "The Pennsylvania site is one of four US-based manufacturing sites J&J plans to build over the next four years.",
    "url": "https://finnhub.io/api/news?id=8bf5234af5b70deda5c96f0706e04ac1f5121521f74ff941319854ff1cf0b074",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771502532,
      "headline": "J&J to build $1bn US CGT manufacturing site in Pennsylvania",
      "id": 139146167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Pennsylvania site is one of four US-based manufacturing sites J&J plans to build over the next four years.",
      "url": "https://finnhub.io/api/news?id=8bf5234af5b70deda5c96f0706e04ac1f5121521f74ff941319854ff1cf0b074"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
    "summary": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
    "url": "https://finnhub.io/api/news?id=96e3fc6efdb528d07fa429fb29b2395f0f2ca3d29500e1fba64ce68321874c99",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771500536,
      "headline": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
      "id": 139149509,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=96e3fc6efdb528d07fa429fb29b2395f0f2ca3d29500e1fba64ce68321874c99"
    }
  },
  {
    "ts": null,
    "headline": "J&J to invest more than $1B in Pennsylvania plant",
    "summary": "The cell therapy plant will support more than 500 biomanufacturing jobs in Montgomery County.",
    "url": "https://finnhub.io/api/news?id=f060622fbcff48ba11751329b2b959caffe32e4a6ac478b251ce7242640c707b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771495740,
      "headline": "J&J to invest more than $1B in Pennsylvania plant",
      "id": 139161261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The cell therapy plant will support more than 500 biomanufacturing jobs in Montgomery County.",
      "url": "https://finnhub.io/api/news?id=f060622fbcff48ba11751329b2b959caffe32e4a6ac478b251ce7242640c707b"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Yield CEFs To Enhance Your Retirement Income",
    "summary": "2 High-Yield CEFs To Enhance Your Retirement Income",
    "url": "https://finnhub.io/api/news?id=2725bbfe792d6a5c54b64bea0dc80f6ea2ff09e1f58740db1f59be7f38472d49",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771492500,
      "headline": "2 High-Yield CEFs To Enhance Your Retirement Income",
      "id": 139146979,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2725bbfe792d6a5c54b64bea0dc80f6ea2ff09e1f58740db1f59be7f38472d49"
    }
  },
  {
    "ts": null,
    "headline": "Walmart earnings, Fed meeting minutes, Zuckerberg's testimony and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=d5cbb412f1268e8edfc3dfb9378edc94627545845f737fbb331cd6f794c158d5",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771489201,
      "headline": "Walmart earnings, Fed meeting minutes, Zuckerberg's testimony and more in Morning Squawk",
      "id": 139149688,
      "image": "https://image.cnbcfm.com/api/v1/image/108266955-1771442352852-108266955-1771442166552-gettyimages-2261796700-021826_connelly_zuckerbergcourt009.jpeg?v=1771465909&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=d5cbb412f1268e8edfc3dfb9378edc94627545845f737fbb331cd6f794c158d5"
    }
  }
]